378 related articles for article (PubMed ID: 37450117)
21. Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non-small cell lung cancer: Analysis of over 8000 cases.
Mack PC; Banks KC; Espenschied CR; Burich RA; Zill OA; Lee CE; Riess JW; Mortimer SA; Talasaz A; Lanman RB; Gandara DR
Cancer; 2020 Jul; 126(14):3219-3228. PubMed ID: 32365229
[TBL] [Abstract][Full Text] [Related]
22. Tumor-educated platelet as liquid biopsy in lung cancer patients.
Liu L; Lin F; Ma X; Chen Z; Yu J
Crit Rev Oncol Hematol; 2020 Feb; 146():102863. PubMed ID: 31935617
[TBL] [Abstract][Full Text] [Related]
23. Liquid biopsy of fine-needle aspiration supernatant for lung cancer genotyping.
Guibert N; Tsukada H; Hwang DH; Chambers E; Cibas ES; Bale T; Supplee J; Ulrich B; Sholl LM; Paweletz CP; Oxnard GR
Lung Cancer; 2018 Aug; 122():72-75. PubMed ID: 30032849
[TBL] [Abstract][Full Text] [Related]
24. Future Perspectives in Detecting
Ferreira D; Miranda J; Martins-Lopes P; Adega F; Chaves R
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33916986
[TBL] [Abstract][Full Text] [Related]
25. Circulating tumor DNA testing in advanced non-small cell lung cancer.
Moding EJ; Diehn M; Wakelee HA
Lung Cancer; 2018 May; 119():42-47. PubMed ID: 29656751
[TBL] [Abstract][Full Text] [Related]
26. Liquid Biopsy in NSCLC: An Investigation with Multiple Clinical Implications.
Bertoli E; De Carlo E; Basile D; Zara D; Stanzione B; Schiappacassi M; Del Conte A; Spina M; Bearz A
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445976
[TBL] [Abstract][Full Text] [Related]
27. Feasibility of liquid biopsy using plasma and platelets for detection of anaplastic lymphoma kinase rearrangements in non-small cell lung cancer.
Park CK; Kim JE; Kim MS; Kho BG; Park HY; Kim TO; Shin HJ; Cho HJ; Choi YD; Oh IJ; Kim YC
J Cancer Res Clin Oncol; 2019 Aug; 145(8):2071-2082. PubMed ID: 31154543
[TBL] [Abstract][Full Text] [Related]
28. Discovery of Targetable Genetic Alterations in NSCLC Patients with Different Metastatic Patterns Using a MassARRAY-Based Circulating Tumor DNA Assay.
Belloum Y; Janning M; Mohme M; Simon R; Kropidlowski J; Sartori A; Irwin D; Westphal M; Lamszus K; Loges S; Riethdorf S; Pantel K; Wikman H
Cells; 2020 Oct; 9(11):. PubMed ID: 33105541
[TBL] [Abstract][Full Text] [Related]
29. Feasibility of cell-free circulating tumor DNA testing for lung cancer.
Santarpia M; Karachaliou N; González-Cao M; Altavilla G; Giovannetti E; Rosell R
Biomark Med; 2016; 10(4):417-30. PubMed ID: 26974841
[TBL] [Abstract][Full Text] [Related]
30. Use of Liquid Biopsy in the Care of Patients with Non-Small Cell Lung Cancer.
Romero A; Serna-Blasco R; Calvo V; Provencio M
Curr Treat Options Oncol; 2021 Aug; 22(10):86. PubMed ID: 34424428
[TBL] [Abstract][Full Text] [Related]
31. Advances in liquid biopsy-based markers in NSCLC.
Ren XD; Su N; Sun XG; Li WM; Li J; Li BW; Li RX; Lv J; Xu QY; Kong WL; Huang Q
Adv Clin Chem; 2023; 114():109-150. PubMed ID: 37268331
[TBL] [Abstract][Full Text] [Related]
32. Next-generation sequencing for tumor mutation quantification using liquid biopsies.
Provencio M; Pérez-Barrios C; Barquin M; Calvo V; Franco F; Sánchez E; Sánchez R; Marsden D; Cristóbal Sánchez J; Martin Acosta P; Laza-Briviesca R; Cruz-Bermúdez A; Romero A
Clin Chem Lab Med; 2020 Jan; 58(2):306-313. PubMed ID: 31469650
[TBL] [Abstract][Full Text] [Related]
33. Role of Circulating Tumor DNA Profiling in Patients with Non-Small Cell Lung Cancer Treated with EGFR Inhibitor.
Ku BM; Kim YJ; Park D; Lee SH; Ahn JS; Park K; Ahn MJ; Sun JM
Oncology; 2022; 100(4):228-237. PubMed ID: 35196661
[TBL] [Abstract][Full Text] [Related]
34. Different Liquid Biopsies for the Management of Non-Small Cell Lung Cancer in the Mutational Oncology Era.
Palmieri M; Frullanti E
Med Sci (Basel); 2023 Jan; 11(1):. PubMed ID: 36649045
[TBL] [Abstract][Full Text] [Related]
35. Utility of Liquid Biopsy by Improved PNA-LNA PCR Clamp Method for Detecting EGFR Mutation at Initial Diagnosis of Non-Small-Cell Lung Cancer: Observational Study of 190 Consecutive Cases in Clinical Practice.
Ito K; Suzuki Y; Saiki H; Sakaguchi T; Hayashi K; Nishii Y; Watanabe F; Hataji O
Clin Lung Cancer; 2018 Mar; 19(2):181-190. PubMed ID: 29174086
[TBL] [Abstract][Full Text] [Related]
36. A Phase II Trial of Osimertinib in the Second-Line Treatment of Non-small Cell Lung Cancer with the EGFR T790M Mutation, Detected from Circulating Tumor DNA: LiquidLung-O-Cohort 2.
Park CK; Cho HJ; Choi YD; Oh IJ; Kim YC
Cancer Res Treat; 2019 Apr; 51(2):777-787. PubMed ID: 30189719
[TBL] [Abstract][Full Text] [Related]
37. Liquid biopsy on the horizon in immunotherapy of non-small cell lung cancer: current status, challenges, and perspectives.
Yang Y; Liu H; Chen Y; Xiao N; Zheng Z; Liu H; Wan J
Cell Death Dis; 2023 Mar; 14(3):230. PubMed ID: 37002211
[TBL] [Abstract][Full Text] [Related]
38. Extracellular vesicle-derived DNA for performing EGFR genotyping of NSCLC patients.
Hur JY; Kim HJ; Lee JS; Choi CM; Lee JC; Jung MK; Pack CG; Lee KY
Mol Cancer; 2018 Jan; 17(1):15. PubMed ID: 29374476
[TBL] [Abstract][Full Text] [Related]
39. Immunotherapy in nonsmall-cell lung cancer: current status and future prospects for liquid biopsy.
Brozos-Vázquez EM; Díaz-Peña R; García-González J; León-Mateos L; Mondelo-Macía P; Peña-Chilet M; López-López R
Cancer Immunol Immunother; 2021 May; 70(5):1177-1188. PubMed ID: 33113004
[TBL] [Abstract][Full Text] [Related]
40. Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma.
Rybarczyk-Kasiuchnicz A; Ramlau R; Stencel K
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435596
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
